$31.38
-0.14-0.46%
At close: -
$27.87
-3.51-11.19%
After Hours: Nov 29, 2:50 PM EDT
Comments
Loading...
Latest news for Capitol Series Trust The Nightview Fund NITE (ARCA:NITE)
Capitol Series Trust The Nightview Fund NITE (ARCA: NITE)
Categories: All
Tuesday, December 03, 2024
Tuesday, November 05, 2024
Wednesday, October 16, 2024
Friday, October 11, 2024
Friday, September 27, 2024
Monday, September 09, 2024
Thursday, September 05, 2024
Wednesday, August 21, 2024
Wednesday, July 17, 2024
Monday, July 01, 2024
Wednesday, June 05, 2019
Wednesday, May 29, 2019
Wednesday, May 08, 2019
Wednesday, March 27, 2019
Monday, March 25, 2019
Sunday, March 10, 2019
Tuesday, March 05, 2019
- Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar
- 10 Biggest Price Target Changes For Tuesday
- Benzinga's Top Upgrades, Downgrades For March 5, 2019
- Benzinga Pro's Top 10 Most-Searched Tickers F...
- SVB Leerink Downgrades Nightstar Therapeutics to Market Perform, Lowers Price Target to $25.50
- Mizuho Downgrades Nightstar Therapeutics to Neutral, Raises Price Target to $25.50
- A Peek Into The Markets: US Stock Futures Up; Target Beats Q4 Estimates
- UBS Downgrades Nightstar Therapeutics to Neutral, Raises Price Target to $25.50
- BMO Capital Downgrades Nightstar Therapeutics to Market Perform, Lowers Price Target to $25.50
- 62 Biggest Movers From Yesterday
Monday, March 04, 2019
- Mid-Afternoon Market Update: Nightstar Therapeutics Surges On Acquisition News; Evoke Pharma Shares Plunge
- 50 Stocks Moving In Monday's Mid-Day Session
- Mid-Day Market Update: U.S. Stocks Turn Negative; Dow Down Over 350 Points
- Mid-Morning Market Update: Markets Open Higher; Childrens Place Misses Q4 Expectations
- 10 Biggest Price Target Changes For Monday
- Biogen Bets On Gene Therapy, Agrees To Acquire Nightstar For $800M
- Benzinga's Top Upgrades, Downgrades For March 4, 2019
- 30 Stocks Moving In Monday's Pre-Market Session
- Nightstar Therapeutics shares are trading hig...
- Cantor Fitzgerald Downgrades Nightstar Therapeutics to Neutral, Lowers Price Target to $25.50
- A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
- Nightstar Therapeutics Announces Agreement to be Acquired by Biogen for $25.50/Share in Cash